Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 9/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.30 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955538 | 1.00 | ELANE (0.33) | ELANESYKCNR2CNR1AADAT | |
| SCHEMBL14955838 | 0.88 | SYK (0.40) | SYKCNR2AADAT | |
| SCHEMBL14955843 | 0.88 | SYK (0.40) | SYKCNR2AADAT | |
| SCHEMBL14956019 | 0.79 | SYK (0.49) | SYK | |
| SCHEMBL14956024 | 0.79 | SYK (0.49) | SYK | |
| SCHEMBL14955555 | 0.75 | SYK (0.40) | SYKPIP4K2A | |
| SCHEMBL14955553 | 0.75 | SYK (0.40) | SYKPIP4K2A | |
| SCHEMBL14955256 | 0.75 | CCR1 (0.38) | SYK | |
| SCHEMBL14955261 | 0.75 | CCR1 (0.38) | SYK | |
| SCHEMBL14955392 | 0.74 | BTK (0.40) | SYKCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782579-B1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARM INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| EP-2782579-A1 | PYRAZINE KINASE INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013078466-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | SYK, ZAP70, LCK | ELANE 3688/4885SYK 1/4885CNR2 3697/4885 |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | SYK, ZAP70, LCK | ELANE 3688/4885SYK 1/4885CNR2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.